{
    "nct_id": "NCT06760637",
    "official_title": "AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)",
    "inclusion_criteria": "* Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent.\n* Documented estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumor\n* Documented HER2-negative tumor\n* Previously untreated with any systemic anticancer therapy for their locally advanced or metastatic disease.\n* Measurable disease or non-measurable bone only disease as defined by RECIST version 1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* In visceral crisis at risk of immediately life-threatening complications in the short term.\n* Current or past history of central nervous system metastases.\n* Have received prior (neo)adjuvant endocrine therapy (ET) and had recurrence during or within 12 months after the last dose of ET.\n* Have received prior (neo)adjuvant CDK4/6i and had recurrence during or within 12 months after the last dose of CDK4/6i.\n* Inadequate renal function, hepatic dysfunction, or hematologic abnormalities.",
    "miscellaneous_criteria": ""
}